Tysabri Uniunea Europeană - română - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Tyruko Uniunea Europeană - română - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

TYSABRI 150mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

tysabri 150mg

biogen (denmark) manufacturing aps - danemarca - natalizumabum - sol. inj. in seringa preumpluta - 150mg - imunosupresoare imunosupresoare selective

TYSABRI 300mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

tysabri 300mg

biogen (denmark) manufacturing aps - danemarca - natalizumabum - conc. pt. sol. perf. - 20mg/ml - imunosupresoare imunosupresoare selective